Moderna Reports Revenue Growth, but Posts Net Loss

Moderna increased its revenue in the first quarter of 2024 compared to the prior period, yet recorded a net loss. The revenue rise was attributed to higher sales of its COVID‑19 vaccine and the early approval of new vaccine candidates. The primary driver of the net loss was identified as high research and development expenses coupled with rising operating costs. Despite the revenue growth, the gross profit margin remained under pressure from these expenditures. The company announced its plans for the upcoming period, focusing on cost control and new product development strategies. Moderna aims to strengthen its cash flow by implementing operational efficiency measures. Investors are closely monitoring the company’s financial report and assessing expectations for future performance. This is not investment advice.

📊 MRNA — Piyasa Yorumu

■ neutral · 60%

Moderna's revenue growth is a positive signal for investors, but the recorded net loss raises concerns about stability. Technical indicators are above the 20- and 50-day moving averages, and the MACD is above its signal line, indicating short-term upward momentum. The RSI is at 63, close to overbought territory but not yet excessive, suggesting the price may still see a brief correction. The price is expected to continue with a slight rise within 1-3 days, though volatility may occur due to the net loss news. Overall, market reaction is balanced, making it difficult to determine a clear short-term direction.

RSI 14

63.0

MACD

0.54

24h Δ

9.32%

Canlı Grafikler